Quick Answer
Retatrutide has been studied as a once-weekly injectable compound. In the Phase 2 obesity trial, researchers used 1 mg, 4 mg, 8 mg, and 12 mg dose groups over 48 weeks. Lilly's Phase 3 updates describe step-wise escalation toward target doses such as 4 mg, 9 mg, and 12 mg, depending on the study.
The important point is not that one number is "the" dose. Retatrutide dosing in the evidence base is a trial-design question: starting dose, escalation, target dose, treatment duration, and monitoring all matter.
Explore the AminoRank retatrutide profileReview linked studies, category details, and vendor availability for retatrutide.View retatrutide profileTrial Dose Ranges
The most-cited Phase 2 obesity trial studied once-weekly retatrutide for 48 weeks in 338 adults with obesity or overweight and weight-related conditions, excluding type 2 diabetes. The trial included 1 mg, 4 mg, 8 mg, and 12 mg groups, with several arms starting lower before reaching the target dose.
That structure matters because the response was dose related. The highest-dose group reached 24.2% mean weight reduction at 48 weeks, while lower-dose groups produced smaller average reductions. Dose was not just a label; it was part of the efficacy and tolerability story.
| Study context | Dosing detail |
|---|---|
| Phase 2 obesity study | Once-weekly retatrutide groups included 1 mg, 4 mg, 8 mg, and 12 mg target-dose arms. |
| Escalation groups | Some groups used lower starting doses before reaching target doses. |
| Phase 3 TRIUMPH-4 | Lilly described starting at 2 mg once weekly and escalating every four weeks toward 9 mg or 12 mg target doses. |
| TRANSCEND-T2D-1 | Lilly reported 4 mg, 9 mg, and 12 mg groups in adults with type 2 diabetes. |
The public dose language is therefore broader than a single "retatrutide dose." It includes starting dose, escalation pace, target dose, duration, and the population being studied.
Why Dose Escalation Matters
Dose escalation is central to retatrutide because the compound is potent and GI effects are the main tolerability issue. Lilly's Phase 2 update said gastrointestinal side effects were the most commonly reported adverse events and usually occurred during escalation.
Escalation lets researchers push toward effective doses while tracking nausea, diarrhea, vomiting, appetite changes, discontinuations, and overall response. Without that schedule context, the milligram number is incomplete.
That is why a bare dose chart can be misleading. A 12 mg target reached after escalation is not the same thing as starting at 12 mg. The schedule is part of the tolerability strategy.
Dosing For Weight-Loss Research
For weight-loss research, retatrutide dosing has produced a clear pattern: higher target doses have produced larger average weight reductions in the public obesity data. The Phase 2 12 mg group reached 24.2% mean weight reduction at 48 weeks. TRIUMPH-4 later reported 28.7% mean weight reduction at 68 weeks with 12 mg in adults with obesity or overweight and knee osteoarthritis.
Those numbers are why dosing gets so much attention. Retatrutide's dose-response story is one of the reasons it stands out in the incretin category.
For schedule-specific detail, see retatrutide dosage schedule. For tolerability context, see retatrutide side effects.
Phase 3 Dosing Context
TRIUMPH-4 gives the clearest public Phase 3 schedule detail so far. Lilly described participants starting at 2 mg once weekly and increasing every four weeks until reaching target doses of 9 mg or 12 mg. Both doses met primary and key secondary endpoints, with the 12 mg group producing the larger reported weight reduction.
TRANSCEND-T2D-1 adds a diabetes-specific view. Lilly reported 4 mg, 9 mg, and 12 mg groups at 40 weeks, with A1C reductions up to 2.0% and weight reductions up to 16.8%.
Dosing Is Different From Reconstitution Math
Retatrutide dosing and reconstitution math often get mixed together, but they answer different questions. Clinical dosing means the amount used in a study protocol. Reconstitution math means concentration after liquid is added to a vial.
That distinction is practical. A 10 mg vial is not the same thing as a 10 mg clinical dose. Vial amount, liquid volume, concentration, and syringe units are math questions, not evidence-based dosing recommendations.
Use the peptide calculatorCalculate concentration and syringe-unit math for research planning.Open calculatorRetatrutide 10 Mg And Microdosing Questions
Retatrutide 10 mg usually appears in vendor or vial-size discussions, not in the main clinical-trial dose language. The public trial doses most readers ask about are 1 mg, 4 mg, 8 mg, 9 mg, and 12 mg, depending on the study.
Microdosing is different. The main published studies used defined trial arms and escalation schedules. If a microdosing approach is not tied to a credible clinical source, it should be treated as informal discussion rather than evidence.
This is a useful place to be strict about language. "10 mg retatrutide" can mean a vial amount, a listing size, or a hypothetical calculation. It should not be automatically read as a clinical-trial dose.
Availability After The Evidence
Once the trial-dose context is clear, availability can be evaluated separately. Vendor research should focus on documentation, pricing, payment options, and shipping rather than treating a vial size as a clinical protocol.
Compare retatrutide research vendorsBrowse vendors by COAs, reviews, discounts, shipping, and payment options.View retatrutide vendorsFAQ
What retatrutide dose did clinical trials study?
Published Phase 2 obesity research studied once-weekly retatrutide groups including 1 mg, 4 mg, 8 mg, and 12 mg. Later Lilly Phase 3 updates describe additional target-dose structures by trial.
Is this a dosing protocol?
No. It summarizes clinical-trial dose language and does not provide personal-use dosing instructions.
Why do retatrutide trials increase dose over time?
Researchers use escalation to study tolerability and response under monitored trial conditions.
Where can I compare retatrutide research vendors?
Compare research vendors by COAs, reviews, discounts, payment methods, shipping, country, and listing detail.